Nuevolution AB (publ) annual report 2017 – correction of English version

Stockholm, 26 February 2018. Nuevolution AB (publ)’s annual report 2017 in English, released on 22 February 2018, contained an inconsistency compared with the Swedish annual report 2017 in the table “Proposed appropriation of profits” (on page 21 of the English report). The prevailing language in the annual report 2017 in Swedish was correctly stated.

The corrected annual report 2017 in English can be found in the attached document as well as through the following link: https://nuevolution.com/wpcontent/uploads/2018/02/Annual-Report-2017-UK-Final.pdf

For more information, please contact:
Alex Haahr Gouliaev, CEO
Phone: +45 3913 0902
Email: ahg@nuevolution.com

Henrik Damkjær Simonsen, CFO
Phone: +45 3913 0947
Email: hs@nuevolution.com

Information about Nuevolution AB (publ)
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the Securities Market Act. The information was sent for publication on Monday 26 February at 16:45 (CET).

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com